LLY vs RMD

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

ResMed Inc. (RMD) continues to demonstrate robust performance as a global leader in sleep apnea and respiratory care. Its Q3 FY2026 results showed healthy 10.8% YoY revenue growth, EPS beat ($2.86 vs $2.79 consensus), and gross margin expansion to 62.8%. These are strong indicators of a well-managed, profitable company in an established healthcare sector. However, this analysis specifically target...